Journal
CANCER LETTERS
Volume 280, Issue 2, Pages 160-167Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.02.028
Keywords
Acetylation; Proteasomal degradation; STATs; NF-kappaB; Signaling crosstalk
Categories
Funding
- Deutsche Forschungsgerneinschaft [SFB 604]
Ask authors/readers for more resources
Histone deacetylases (HDACs) play an important role in gene regulation. Inhibitors of HDACs (HDACi) are novel anti-cancer drugs, which induce histone (hyper-) acetylation and Counteract aberrant gene repression. On the other hand, HDACi treatment can also result in decreased gene expression, and targeting HDACs affects more than chromatin. Recently, HDACi were shown to evoke non-histone protein acetylation, which can alter signaling networks relevant for tumorgenesis. Furthermore, HDACi can promote the degradation of (proto-) oncoproteins. Here, we summarize these findings and discuss how these substances could be beneficial for the treatment and prevention of human ailments, such as cancer and unbalanced immune functions. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available